Sibutramine/zolpidem interaction

February 2014
Reactions Weekly;Feb2014, Vol. 1488 Issue 1, p31
The article presents a case study of a 61-year old woman who suffered from two psychotic episodes during treatment with sibutramine for obesity.


Related Articles

  • Sibutramine.  // Reactions Weekly;Feb2014, Vol. 1488 Issue 1, p31 

    The article presents a case study of a 43-year old woman who developed life-threatening psychosis following a drink of slimming coffee contaminated with sibutramine.

  • Sibutramine.  // Reactions Weekly;Nov2015, Vol. 1576 Issue 1, p226 

    The article presents a case study of a 27-year-old woman who developed psychosis during treatment with Pai You Guo slimming capsules adulterated with sibutramine.

  • THIN AT WHAT COST? CASE REPORTS OF SIBUTRAMINE-INDUCED PSYCHOTIC DISORDERS. Basu, Sutapa; Verma, Swapna // ASEAN Journal of Psychiatry;Jul-Dec2014, Vol. 15 Issue 2, p213 

    Objective: The objective of these 4 case reports is to highlight that psychotic symptom can occur due to the consumption of sibutramine. The psychosis is usually self-remitting, once its consumption is stopped. Methods: All cases with first episode psychosis presenting to a tertiary mental...

  • A Randomized Trial of Sibutramine in the Management of Obese Type 2 Diabetic patients Treated With Metformin. McNulty, Steven J.; Ur, Ehud; Williams, Gareth // Diabetes Care;Jan2003, Vol. 26 Issue 1, p125 

    OBJECTIVE To evaluate the effects of sibutramine (15 and 20 mg/day) on weight, metabolic control, and blood pressure in metformin-treated obese subjects with type 2 diabetes. RESEARCH DESIGN AND METHODS — A 12-month randomized prospective placebo-controlled double-blind study was...

  • Cardiovascular Effects of Pharmacologic Treatments for Obesity. Aronne, Louis J. // Nutrition in Clinical Care;Jan/Feb98 Supplement 1, Vol. 1 Issue 1, p51 

    Examines the cardiovascular effects of pharmacologic treatment for obesity in the United States. Complications of obesity; Development of sibutramine as an antidepressant; Association between sibutramine and heart disease and hypertension.

  • Continuous and intermittent sibutramine were equally effective at 44 weeks for reducing weight in obese persons. Cheskin, Lawrence J. // ACP Journal Club;Mar/Apr2002, Vol. 136 Issue 2, p49 

    Presents information on a study which examined the effectiveness of sibutramine for reducing weight in obese patients. Methodology of the study; Results; Comments on the study.

  • Sibutramine safety review.  // WHO Drug Information;2002, Vol. 16 Issue 1, p26 

    Reports on action taken by regulatory agencies of various countries regarding the prescription drug sibutramine. Approval of the drug in Canada in December 2000 to treat obesity; Italian authorities' temporary suspension of market authorization of all drugs containing sibutramine in March 2002;...

  • Pharmacological Treatment of Obesity: Current Standards and Future Perspectives. Romijn, J. A.; Smit, J. W. A.; Pereira, A. M.; Corssmit, E. P. M.; Pijl, H. // Immunology, Endocrine & Metabolic Agents - Medicinal Chemistry;Feb2006, Vol. 6 Issue 1, p119 

    The long-term effects on weight have only been studied for orlistat and sibutramine. The net effects of these drugs vary between 2-5% loss of weight after 1-2 years of treatment. However, the effects of orlistat and sibutramine on morbidity and mortality have not been studied extensively. In the...

  • FROM THE ANALYST'S COUCH: Obesity market overview. Farrigan, Christine; Pang, Kevin // Nature Reviews Drug Discovery;Apr2002, Vol. 1 Issue 4, p257 

    Presents an overview of available pharmacological therapies for obesity. Sibutramine; Axokine; Bupropion; Recombinant human leptin; Topiramate; Forecast of sales of antiobesity agents by 2010.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics